Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy.

Izzy M, Jibara G, Aljanabi A, Alani M, Giannattasio E, Zaidi H, Said Z, Gaglio P, Wolkoff A, Reinus JF.

J Clin Exp Hepatol. 2016 Jun;6(2):100-8. doi: 10.1016/j.jceh.2016.02.006. Epub 2016 Mar 12.

PMID:
27493457
2.

Spectrum of Alcoholic Liver Disease.

Chacko KR, Reinus J.

Clin Liver Dis. 2016 Aug;20(3):419-27. doi: 10.1016/j.cld.2016.02.002. Epub 2016 May 31. Review.

PMID:
27373606
3.

Extrahepatic Complications of Nonalcoholic Fatty Liver Disease.

Chacko KR, Reinus J.

Clin Liver Dis. 2016 May;20(2):387-401. doi: 10.1016/j.cld.2015.10.004. Epub 2016 Feb 18. Review.

PMID:
27063276
4.

Commentary: real-world triple therapy experience treating hepatitis C virus - authors' reply.

Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF.

Aliment Pharmacol Ther. 2014 Mar;39(5):543. doi: 10.1111/apt.12641. No abstract available.

5.

Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir.

Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF.

Aliment Pharmacol Ther. 2014 Jan;39(2):209-16. doi: 10.1111/apt.12560. Epub 2013 Nov 24.

6.

Expedited liver allocation in the United States: a critical analysis.

Kinkhabwala M, Lindower J, Reinus JF, Principe AL, Gaglio PJ.

Liver Transpl. 2013 Oct;19(10):1159-65. doi: 10.1002/lt.23675. Epub 2013 Jul 8.

7.

Prevalence and natural history of alcoholic liver disease.

Schwartz JM, Reinus JF.

Clin Liver Dis. 2012 Nov;16(4):659-66. doi: 10.1016/j.cld.2012.08.001. Review.

PMID:
23101975
8.

Value of noncontrast CT immediately after transarterial chemoembolization of hepatocellular carcinoma with drug-eluting beads.

Golowa YS, Cynamon J, Reinus JF, Kinkhabwala M, Abrams M, Jagust M, Chernyak V, Kaubisch A.

J Vasc Interv Radiol. 2012 Aug;23(8):1031-5. doi: 10.1016/j.jvir.2012.04.020. Epub 2012 Jun 26.

PMID:
22739645
9.

Response-guided telaprevir combination treatment for hepatitis C virus infection.

Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team.

N Engl J Med. 2011 Sep 15;365(11):1014-24. doi: 10.1056/NEJMoa1014463. Erratum in: N Engl J Med. 2011 Oct 20;365(16):1551.

10.

Social barriers to listing for adult liver transplantation: their prevalence and association with program characteristics.

Flattau A, Olaywi M, Gaglio PJ, Marcus P, Meissner P, L Dorfman EB, Reinus JF.

Liver Transpl. 2011 Oct;17(10):1167-75. doi: 10.1002/lt.22357.

11.

Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use.

Gaglio PJ, Moss N, McGaw C, Reinus J.

Dig Dis Sci. 2011 May;56(5):1509-15. doi: 10.1007/s10620-011-1604-3. Epub 2011 Feb 19.

12.

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients.

Feuerstadt P, Bunim AL, Garcia H, Karlitz JJ, Massoumi H, Thosani AJ, Pellecchia A, Wolkoff AW, Gaglio PJ, Reinus JF.

Hepatology. 2010 Apr;51(4):1137-43. doi: 10.1002/hep.23429.

PMID:
20049907
13.

Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization.

Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T.

J Virol. 2007 Aug;81(15):8072-9. Epub 2007 May 16.

14.

Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions.

Bertaux C, Daelemans D, Meertens L, Cormier EG, Reinus JF, Peumans WJ, Van Damme EJ, Igarashi Y, Oki T, Schols D, Dragic T, Balzarini J.

Virology. 2007 Sep 15;366(1):40-50. Epub 2007 May 11.

15.

Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.

Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP, Zajecka JM, Bruno CJ, Henderson MA, Reinus JF, Evans DL, Asnis GM, Miller AH.

Aliment Pharmacol Ther. 2007 May 15;25(10):1163-74.

16.

Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis.

Gassert DJ, Garcia H, Tanaka K, Reinus JF.

Dig Dis Sci. 2007 Sep;52(9):2433-7. Epub 2007 Apr 12.

PMID:
17429719
17.

Hippocratic Economics (the Physician's Dilemma).

Reinus WR, Reinus JF.

J Am Coll Radiol. 2005 Aug;2(8):670-5.

PMID:
17411903
18.

Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats.

De La Garza R 2nd, Asnis GM, Pedrosa E, Stearns C, Migdal AL, Reinus JF, Paladugu R, Vemulapalli S.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):781-92.

PMID:
15927336
19.

Interferon for hepatitis C patients with psychiatric disorders.

Asnis GM, De La Garza R, Rego SA, Henderson MA, Reinus JF.

Am J Psychiatry. 2004 Dec;161(12):2332; author reply 2332-4. No abstract available.

PMID:
15569920
20.

Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection.

Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS.

J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1367-75.

PMID:
15483466
Items per page

Supplemental Content

Loading ...
Write to the Help Desk